Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Absolute Quantification of Donor-Derived Cell-Free DNA as a Marker of Rejection and Graft Injury in Kidney Transplantation - Results From a Prospective Observational Study.

Oellerich M, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J.

Am J Transplant. 2019 May 7. doi: 10.1111/ajt.15416. [Epub ahead of print]

PMID:
31062511
2.

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S.

Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640.

PMID:
31045868
3.

Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?

Wieland E, Shipkova M.

Ther Drug Monit. 2019 Apr;41(2):180-191. doi: 10.1097/FTD.0000000000000594.

PMID:
30883512
4.

Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring.

Shipkova M, Christians U.

Ther Drug Monit. 2019 Apr;41(2):111-114. doi: 10.1097/FTD.0000000000000627.

PMID:
30883504
5.

Pharmacokinetic and pharmacodynamic drug monitoring of direct acting oral anticoagulants: Where do we stand?

Wieland E, Shipkova M.

Ther Drug Monit. 2018 Dec 18. doi: 10.1097/FTD.0000000000000594. [Epub ahead of print]

PMID:
30570513
6.

Evaluation of an Ion Trap Toxtyper Liquid Chromatography With An Ion Trap Mass Spectrometric Instrument (Toxtyper) for Drug of Abuse Screening in Oral Fluid.

Plecko T, Berbalk K, Wieland E, Shipkova M.

Ther Drug Monit. 2018 Oct;40(5):642-648. doi: 10.1097/FTD.0000000000000544.

PMID:
30212416
7.

Multicenter Evaluation of a New Electrochemiluminescence Immunoassay for Everolimus Concentrations in Whole Blood.

Verstraete AG, Rigo-Bonnin R, Wallemacq P, Vogeser M, Schuetzenmeister A, Schmiedel C, Shipkova M.

Ther Drug Monit. 2018 Feb;40(1):59-68. doi: 10.1097/FTD.0000000000000474.

PMID:
29210975
8.

Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation.

Stove V, Ramos PA, Wallemacq P, Vogeser M, Schuetzenmeister A, Schmiedel C, Shipkova M.

Clin Chem Lab Med. 2018 Apr 25;56(5):764-775. doi: 10.1515/cclm-2017-0583.

9.

Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate.

Rieger H, Schmidt P, Schaeffeler E, Abe M, Schiffhauer M, Schwab M, von Ahsen N, Zurek G, Kirchherr H, Shipkova M, Wieland E.

Clin Chem Lab Med. 2018 Apr 25;56(5):803-809. doi: 10.1515/cclm-2017-0670.

PMID:
29194039
10.

Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.

Arns W, Huppertz A, Rath T, Ziefle S, Rump LC, Hansen A, Budde K, Lehner LJ, Shipkova M, Baeumer D, Kroeger I, Sieder C, Klein T, Schenker P.

Transplantation. 2017 Nov;101(11):2780-2788. doi: 10.1097/TP.0000000000001843.

PMID:
28658202
11.

Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation.

van Gelder T, Fischer L, Shihab F, Shipkova M.

Transplant Rev (Orlando). 2017 Jul;31(3):151-157. doi: 10.1016/j.trre.2017.02.007. Epub 2017 Feb 27. Review.

12.

Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method.

Shipkova M, Rapp S, Rigo-Bonnin R, Wieland E, Peter A.

Ther Drug Monit. 2017 Apr;39(2):102-108. doi: 10.1097/FTD.0000000000000376.

PMID:
28125504
13.

Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation.

Rissling O, Bauer S, Shipkova M, Glander P, Mai M, Hambach P, Budde K.

Scand J Clin Lab Invest. 2016 Dec;76(8):612-619. Epub 2016 Sep 27.

PMID:
27676419
14.

Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors.

Abdel-Kahaar E, Giese T, Sommerer C, Rieger H, Shipkova M, Wieland E.

Ther Drug Monit. 2016 Dec;38(6):711-716.

PMID:
27661400
15.

Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition.

Abdel-Kahaar E, Kabakchiev M, Hartmann B, Wieland E, Shipkova M.

Clin Biochem. 2016 Oct;49(15):1181-1187. doi: 10.1016/j.clinbiochem.2016.06.012. Epub 2016 Jun 29.

PMID:
27372285
16.

Analytical evaluation of a real-time PCR-based DNA demethylation assay to assess the frequency of naturally occurring regulatory T cells in peripheral blood.

Metzker M, Shipkova M, von Ahsen N, Andag R, Abe M, Canzler O, Klett C, Leicht S, Olbricht C, Wieland E.

Clin Biochem. 2016 Oct;49(15):1173-1180. doi: 10.1016/j.clinbiochem.2016.05.019. Epub 2016 May 21.

PMID:
27220060
17.

LC-MS/MS as a tool for TDM services: Where are we?

Shipkova M, Svinarov D.

Clin Biochem. 2016 Sep;49(13-14):1009-23. doi: 10.1016/j.clinbiochem.2016.05.001. Epub 2016 May 6. Review. No abstract available.

PMID:
27163969
18.

Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee.

Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW, Brunet M, Kunicki PK, Pawiński T, Langman LJ, Marquet P, Oellerich M, Wieland E, Wallemacq P.

Ther Drug Monit. 2016 Apr;38(2):170-89. doi: 10.1097/FTD.0000000000000269. Review.

PMID:
26982493
19.

Therapeutic Drug Monitoring of Everolimus: A Consensus Report.

Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, López OM, Masuda S, Seger C, Picard N, Oellerich M, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P.

Ther Drug Monit. 2016 Apr;38(2):143-69. doi: 10.1097/FTD.0000000000000260.

PMID:
26982492
20.

Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M.

Ther Drug Monit. 2016 Apr;38 Suppl 1:S1-20. doi: 10.1097/FTD.0000000000000287. Review.

PMID:
26977997

Supplemental Content

Loading ...
Support Center